Micromedex NeoFax Essentials
NeoFax Essentials is a reliable resource for on-the-go access to evidence-based drug information to efficiently and safely manage drug therapy for neonatal patients. It allows clinicians to make accurate and more informed treatment decisions at the point of care, while minimizing errors in this vulnerable patient population. This neonatal-specific app has clinical value for doctors, nurses, and pharmacists. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.
Truven Health Analytics is a trusted source for neonatal drug dosing, based on the strict editorial policies and practices that have guided Micromedex for more than 30 years. Evidence-based, fully referenced neonatal-specific drug information enables clinicians to make informed treatment decisions. The drug monographs cover information including: dose, administration, uses, contraindications/precautions, adverse effects, monitoring, pharmacology, special considerations/preparation, solution
- and drug-drug compatibility/incompatibility information, and references. This mobile app also includes a comprehensive enteral formulas component providing nutritional information for approximately 60 different neonatal and infant formulas, and human milk fortifiers. NeoFax Essentials drug information is intended for full-term babies up to 28 days of age (PNA) and preterm babies up to 44 weeks postmenstrual age (GA + PNA).
Do you work at a facility that subscribes to NeoFax online? Check with your Chief of Pediatrics, Director of Pediatrics, Director of the NICU, Directory of Pharmacy, Chief Medical Officer, Chief Nursing Officer, Medical Librarian, or anyone else at your facility responsible for clinical reference information.
If you work at a facility that subscribes to NeoFax online, FREE access to these apps requires a password. To obtain the NeoFax Essentials password email support at [email protected] from an official work email address (Gmail, yahoo, hotmail, etc. will not be accepted).
Category : Medical
Reviews (10)
Originally I had given a bad review because I was charged, but couldn't access the app. I guess IBM saw the complaint and contacted me. They were wonderful with helping me to get the app to work. I do feel IBM could make their tech support easier to find, as the "visit support" doesn't really lead anywhere, but once you have their attention, they will move heaven and earth to help you. Thank you IBM! The Neofax has long been a great reference for neonatal medical providers such as myself!
Fixed! Help desk called me and told me they were working on a fix for the app crashing on Pixel phones running Android 11. Bingo! Within 36 hours their development team had the issue fixed and customer service called me to have me test it. Stellar job all around. I am so very impressed at the lengths they went to address this issue when this program services such a small niche of critical healthcare providers. Kudos to the IBM Micromedex/Neofax crew.
I updated the app and was charged twice. When I try to open it I receive the message that something went wrong. In order to open the app I would have to pay again. I am not paying three times for an app I can't use.
Usually a great app, but new version closes after trying to download new data on Pixel 3a.
Says unable to download data.. both this and pediatric version on my s8+
They say it's free but after you register, it's $29.99! False advertising!!
Advertising for free, but afterwards they ask you to purchase...misleading...
Helpful reference tool when it was working. Won't open now so it's a trashed app for me
Necessary information that is, otherwise, hard to find!
I went to open the App and it said my subscription had expired. I paid to renew and got a message that it was unsuccessful. Tried once more and it did not go through again. Or so I thought. Checked my emails and I was charged twice. Which wouldn't be as bad if I could actually open up the App. I contacted customer service, uninstalled and reinstalled and it still does not work.